MX394911B - Anticuerpo que se une especificamente a erbb3 y uso de este. - Google Patents

Anticuerpo que se une especificamente a erbb3 y uso de este.

Info

Publication number
MX394911B
MX394911B MX2018004228A MX2018004228A MX394911B MX 394911 B MX394911 B MX 394911B MX 2018004228 A MX2018004228 A MX 2018004228A MX 2018004228 A MX2018004228 A MX 2018004228A MX 394911 B MX394911 B MX 394911B
Authority
MX
Mexico
Prior art keywords
erbb3
antibody
specifically binds
antigen
binding fragment
Prior art date
Application number
MX2018004228A
Other languages
English (en)
Other versions
MX2018004228A (es
Inventor
Dong Goo Bae
Mi Rim Hong
Mi Young Kim
Young Mi Hur
Original Assignee
Isu Abxis Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59013461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX394911(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isu Abxis Co Ltd filed Critical Isu Abxis Co Ltd
Publication of MX2018004228A publication Critical patent/MX2018004228A/es
Publication of MX394911B publication Critical patent/MX394911B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un anticuerpo que se une específicamente a ErbB3 o un fragmento de unión al antígeno de este y el uso de estos. El anticuerpo que se une específicamente a ErbB3 o un fragmento de unión al antígeno de este se puede utilizar eficazmente para prevenir o tratar una enfermedad relacionada con la activación o sobreexpresión de la proteína ErbB3.
MX2018004228A 2015-12-07 2016-11-02 Anticuerpo que se une especificamente a erbb3 y uso de este. MX394911B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150173281A KR101746152B1 (ko) 2015-12-07 2015-12-07 ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
PCT/KR2016/012545 WO2017099362A1 (en) 2015-12-07 2016-11-02 Antibody specifically binding to erbb3 and use thereof

Publications (2)

Publication Number Publication Date
MX2018004228A MX2018004228A (es) 2018-05-15
MX394911B true MX394911B (es) 2025-03-24

Family

ID=59013461

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004228A MX394911B (es) 2015-12-07 2016-11-02 Anticuerpo que se une especificamente a erbb3 y uso de este.

Country Status (14)

Country Link
US (1) US10413607B2 (es)
EP (2) EP3362480B1 (es)
JP (2) JP6982574B2 (es)
KR (1) KR101746152B1 (es)
CN (2) CN112472804B (es)
AR (1) AR107012A1 (es)
AU (1) AU2016365506B2 (es)
CA (1) CA3000835C (es)
ES (1) ES2891990T3 (es)
MX (1) MX394911B (es)
PL (1) PL3362480T3 (es)
RU (1) RU2707121C9 (es)
TW (1) TWI615406B (es)
WO (1) WO2017099362A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220275080A1 (en) * 2018-10-17 2022-09-01 Good T Cells, Inc. Binding molecule specific to lrig-1 protein, and use thereof
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0173281B1 (ko) 1996-11-30 1999-02-18 양재신 자동차의 램프 각도 조절장치
PL2129396T3 (pl) * 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
EA022201B1 (ru) * 2008-04-11 2015-11-30 Мерримак Фармасьютикалз, Инк. Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
US8895001B2 (en) * 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
BR112012025730B1 (pt) * 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
PL2606070T3 (pl) 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
AU2012274461A1 (en) * 2011-06-20 2014-01-16 Kyowa Hakko Kirin Co., Ltd. Anti-erbB3 antibody
CA2849508C (en) * 2011-09-30 2020-12-22 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
US11305012B2 (en) * 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof

Also Published As

Publication number Publication date
CN112472804A (zh) 2021-03-12
PL3362480T3 (pl) 2022-01-03
AU2016365506B2 (en) 2019-06-20
EP3778647B1 (en) 2026-02-25
WO2017099362A1 (en) 2017-06-15
JP6982574B2 (ja) 2021-12-17
RU2707121C9 (ru) 2020-06-16
BR112018006900A2 (pt) 2018-10-16
KR101746152B1 (ko) 2017-06-13
EP3362480A1 (en) 2018-08-22
US20180085455A1 (en) 2018-03-29
TW201726742A (zh) 2017-08-01
CA3000835C (en) 2020-06-09
JP2018536026A (ja) 2018-12-06
ES2891990T3 (es) 2022-02-01
RU2018113269A (ru) 2019-10-18
RU2018113269A3 (es) 2019-10-18
JP6989645B2 (ja) 2022-01-05
EP3362480A4 (en) 2019-06-05
US10413607B2 (en) 2019-09-17
CN107683292A (zh) 2018-02-09
AU2016365506A1 (en) 2018-04-12
JP2020117512A (ja) 2020-08-06
CN112472804B (zh) 2024-07-23
EP3778647A1 (en) 2021-02-17
CN107683292B (zh) 2021-06-08
CA3000835A1 (en) 2017-06-15
AU2016365506A9 (en) 2018-11-01
MX2018004228A (es) 2018-05-15
AR107012A1 (es) 2018-03-14
EP3362480B1 (en) 2021-08-04
RU2707121C2 (ru) 2019-11-22
TWI615406B (zh) 2018-02-21

Similar Documents

Publication Publication Date Title
EA202091540A1 (ru) Антитела к lilrb2
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
MX377716B (es) Moduladores de aplnr y usos de estos.
MX2024006564A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
CU24568B1 (es) Anticuerpo inhibidor de masp-3
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
UY37336A (es) Anticuerpos anti-virus del zika y métodos de uso
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201692394A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
MX394170B (es) Anticuerpos anti-transtiretina
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201790339A1 (ru) Комбинированные препараты с антителами к cd40
MX389911B (es) Anticuerpos anti-transtiretina
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
BR112015022123A8 (pt) Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit
EA201991876A1 (ru) Антитела против фактора d и их применения
CL2018000092A1 (es) Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2